Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KADIAN vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mu-opioid receptor agonist; modulates pain perception and emotional response to pain.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
20-100 mg orally every 12 hours; titration based on pain severity and prior opioid exposure.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life of morphine: 2–4 hours; KADIAN extended-release formulation: effective half-life ~12 hours due to prolonged absorption, dosing q12h or q24h
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily via CYP3A4; also undergoes N-demethylation to normorphine.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: primarily as morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G); ~90% of total elimination is renal, with 10% biliary/fecal
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
~30–35% bound, primarily to albumin
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
1.0–4.0 L/kg; wide distribution reflects extensive tissue uptake
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: ~20–40% due to extensive first-pass metabolism
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
GFR 30-60 m L/min: start with 75% of usual dose; GFR <30 m L/min: start with 50% of usual dose and increase cautiously.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: start with 50-75% of usual dose; Child-Pugh Class C: avoid or use with extreme caution.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Not approved for pediatric use; safety and efficacy not established.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Start at lower end of dosing range (e.g., 10-20 mg every 12 hours); monitor for respiratory depression and constipation; consider extended dosing intervals.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion,Neonatal opioid withdrawal syndrome,Cytochrome P450 3A4 interaction,Risks from concomitant use with benzodiazepines or other CNS depressants,Adrenal insufficiency,Severe hypotension,Gastrointestinal effects,Seizures,Avoid in patients with known or suspected gastrointestinal obstruction, including paralytic ileus
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity to morphine sulfate or any component of the product
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid alcohol and any products containing alcohol (e.g., alcoholic beverages, certain mouthwashes, over-the-counter liquid medications) as alcohol can increase the release rate of morphine from the extended-release formulation, risking overdose. Grapefruit juice may theoretically alter morphine metabolism; caution advised. High-fat meals may delay absorption but do not significantly affect overall exposure; take consistently with regard to meals.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
KADIAN (morphine sulfate extended-release) is classified as Pregnancy Category C. First trimester: risks are uncertain but opioid use has been associated with neural tube defects in some studies; however, data for morphine specifically are limited. Second and third trimesters: chronic use may lead to fetal dependence and withdrawal (neonatal abstinence syndrome). Near term: increased risk of respiratory depression in the neonate. Morphine crosses the placenta.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Morphine is excreted into breast milk. The M/P ratio is approximately 2.5:1 for morphine. Breastfeeding is generally considered compatible with caution; monitor infant for respiratory depression, sedation, and withdrawal symptoms. American Academy of Pediatrics considers morphine compatible with breastfeeding, but advise using lowest effective dose for shortest duration.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Pregnancy may increase clearance of morphine due to increased renal blood flow and volume of distribution, potentially requiring higher doses to achieve analgesia. However, no standardized dose adjustments; dose should be individualized based on pain control and side effects. Taper if discontinuing to avoid withdrawal.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
KADIAN is an extended-release morphine formulation requiring q12h dosing; capsules can be opened and sprinkled on applesauce but should not be crushed or chewed. Given the high opioid content, use with caution in opioid-naïve patients; start with lowest available strength. Monitor for respiratory depression, especially during titration. KADIAN levels may be affected by hepatic impairment; reduce dose in moderate to severe hepatic disease. Do not use for as-needed analgesia.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take KADIAN exactly every 12 hours; do not take more frequently.,Swallow capsules whole; if you have trouble, open the capsule and sprinkle the beads onto a small amount of applesauce and swallow immediately without chewing.,Do not crush, chew, or dissolve the capsule contents as that can cause a fatal overdose.,Avoid alcohol and any medicines containing alcohol while taking KADIAN.,Store securely out of reach of children and others; dispose of unused pills via a take-back program.,Do not stop taking abruptly; consult your doctor for a tapering schedule.,Contact your healthcare provider if you experience severe drowsiness, confusion, or difficulty breathing.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KADIAN vs ABSTRAL, answered by our medical review team.
KADIAN is a Opioid Analgesic that works by Mu-opioid receptor agonist; modulates pain perception and emotional response to pain.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KADIAN and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KADIAN is: 20-100 mg orally every 12 hours; titration based on pain severity and prior opioid exposure.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KADIAN and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KADIAN is classified as Category C. KADIAN (morphine sulfate extended-release) is classified as Pregnancy Category C. First trimester: risks are uncertain but opioid use has been associated with neural tube defects i. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.